黄芩苷磷脂复合物固体分散体的药动学研究  

Pharmacokinetics of Baicalin Phospholipid Complex Solid Dispersion

作　　者：杨爱霞[1] 张力凡 鲁力 Yang Aixia;Zhang Lifan;Lu Li(Department of Pharmacy,Wuhan First Hospital,Wuhan 430022,China;School of Pharmacy,Hubei University of Chinese Medicine)

机构地区：[1]武汉市第一医院,武汉430022 [2]湖北中医药大学

出　　处：《中国药师》2020年第7期1331-1334,1362,共5页China Pharmacist

基　　金：卫生计生委科研项目(编号:WZ18E11)。

摘　　要：目的:研究黄芩苷磷脂复合物固体分散体在体内的药动学特征。方法:分别灌胃给予SD大鼠黄芩苷、黄芩苷磷脂复合物及其固体分散体,给药剂量为70 mg·kg^-1。HPLC法测定黄芩苷血药浓度,绘制药-时曲线,DAS2.0计算药动学参数。结果:黄芩苷磷脂复合物固体分散体的平均达峰浓度Cmax为2.707μg·ml^-1,较黄芩苷原料药的Cmax0.745μg·ml^-1与磷脂复合物的Cmax2.219μg·ml^-1,差异均具有统计学意义(P<0.05或P<0.01);黄芩苷磷脂复合物固体分散体组AUC0-t27.182 g·h·ml^-1,较黄芩苷原料药的AUC0-t7.673 g·h·ml^-1与磷脂复合物的AUC0-t20.188 g·h·ml^-1,差异均具有统计学意义(P<0.05或P<0.01)。结论:黄芩苷磷脂复合物制备成固体分散体后,黄芩苷口服生物利用度得到进一步提高。Objective:To study the pharmacokinetics of baicalin phospholipid complex solid dispersion in vivo.Methods:SD rats were respectively given baicalin,baicalin phospholipid complex and the solid dispersion by gavage at a dose of 70 mg·kg^-1.HPLC was used to determine the concentration of baicalin in blood.Drug-time curve was drawn and pharmacokinetic parameters were calculated by DAS 2.0.Results:The average peak concentration(Cmax)of scutellin phospholipid complex solid dispersion was 2.707μg·ml^-1,which was significantly different from that of scutellin API(0.745μg·ml^-1)and phospholipid complex(2.219μg·ml^-1)(P<0.05 or P<0.01).AUC0-tin the solid dispersion group of baicalin phospholipid complex was 27.182μg·h·ml^-1,which was significantly different from that of scutellin API(AUC0-t7.673 g·h·ml^-1)and phospholipid complex(AUC0-t20.188 g·h·ml^-1)(P<0.05 or P<0.01).Conclusion:The bioavailability of baicalin can be further improved after the preparation of solid dispersion with baicalin phospholipid complex.

关 键 词：黄芩苷 磷脂复合物 固体分散体 药动学 

分 类 号：R283.6[医药卫生—中药学] R969.1[医药卫生—中医学]